Labiotech.eu

News and Trends 26 Sep 2022

Mucocort signs deal for pain-relieving mouth ulcer treatment

Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers – aphthous stomatitis. The company has signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort. Aphthous stomatitis is a common disorder. Sixty percent of […]

September 26, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Cuba to receive €46.7M to boost biopharma sector

The Central American Bank for Economic Integration (CABEI) has signed the first financing agreement with the Republic of Cuba for the execution of a project to strengthen the Cuban biopharmaceutical industry. On of the goals of the project is to combat COVID-19. The funding is for a total of €46.7 million ($45 million). The initiative, […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Everest Medicines gets go-ahead for renal disease drug study

Chinese biopharma company Everest Medicines says the China National Medical Products Administration (NMPA)’s Center for Drug Evaluation has approved the investigational new drug (IND) application for a phase 1b study of EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned phase 1b clinical study […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Sep 2022

Grant awarded to help bring to market an innovative treatment for bone cancer

A grant has been awarded to look into the feasibility of bringing to market a new therapy to treat osteosarcoma that aids bone regeneration with fewer side-effects. The European Research Council gave the Proof of Concept grant to professor Cristina Canal from the Technical University of Catalunya’s (UPC) department of materials science and engineering who […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The Oncologic Drugs Advisory Committee (ODAC) has said it does not consider the treatment for patients with relapsed or refractory multiple myeloma (RRMM) favorable in a benefit-risk profile. Oncopeptides AB has been trialing Pepaxto in the […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed. We also have our weekly chat with global […]

September 23, 2022

News and Trends 22 Sep 2022

Study data for glioblastoma treatment confirms safety and tolerability profile

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Research identifies new treatment target for CNS injury and neurological disease

Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. The financing will further support clinical advancement of lead candidate HU6, a first-in-class controlled metabolic accelerator (CMA) designed […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Emyria starts program with neuroscience drug discovery CRO

Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenic’s drug discovery platform, SmartCube. SmartCube extracts and analyzes behavioral and […]

September 22, 2022 - 2 minutesmins - By Jim Cornall

Startup Scout 22 Sep 2022

Cartography Biosciences unearths cancer immunotherapy targets

Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […]

September 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 22 Sep 2022

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

A U.S.-based biotech yesterday (September 21) reported additional biomarker results for a treatment of type 2 diabetes (T2D) from a phase 1 study. Glyscend Therapeutics, has been looking at orally administered drug GLY-200, which is a gut-restricted therapeutic. The company also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New […]

September 22, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Mucocort signs deal for pain-relieving mouth ulcer treatment

Cuba to receive €46.7M to boost biopharma sector

Everest Medicines gets go-ahead for renal disease drug study

Grant awarded to help bring to market an innovative treatment for bone cancer

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

Study data for glioblastoma treatment confirms safety and tolerability profile

Research identifies new treatment target for CNS injury and neurological disease

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Emyria starts program with neuroscience drug discovery CRO

Cartography Biosciences unearths cancer immunotherapy targets

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!